Protocol S抗VEGF算法治疗增殖性糖尿病视网膜病变的原理与应用
结果显示雷珠单抗治疗2年内可获得良好临床结局,仅3只眼符合失败或无效标准;选择抗VEGF或全视网膜光凝作为一线治疗时,应权衡两种疗法优势及患者随访依从性。
要点
- 雷珠单抗治疗后1个月19%患眼新生血管完全消退,6个月52%消退。
- 6个月时新生血管已消退者后续注射次数中位数少于未消退者(4次 vs 7次,P<0.001)。
- 2年内仅3只眼符合失败或无效标准,需启动全视网膜光凝。
核心结论
- DRCR.net的PDR治疗算法在起始抗VEGF治疗后的2年内可提供 excellent 临床结局。
- 选择抗VEGF或全视网膜光凝作为PDR一线治疗时,应权衡两种疗法相对优势及患者对随访和治疗建议的预期依从性。
研究设计与样本
- DRCR.net Protocol S随机临床试验的事后分析。
- 雷珠单抗组191只眼接受0.5mg玻璃体腔注射,与全视网膜光凝组比较。
主要发现
- 雷珠单抗组1个月时19%(35/188)患眼新生血管完全消退,另60%(113/188)改善。
- 6个月时52%(80/153)新生血管消退,3%(4/153)改善,37%(56/153)稳定,8%(13/153)较上次访视恶化。
- 6个月至2年间,6个月时新生血管已消退者注射次数中位数4次(IQR 1-7,n=73),未消退者7次(IQR 4-11,n=67),P<0.001。
- 研究中至少一次满足持续稳定标准的73只眼中68只(93%)暂缓注射,其中62%(42/68)在暂缓后16周内恢复注射。
- 2年时43%(66/154)新生血管消退,5%(7/154)改善,23%(36/154)稳定,27%(42/154)较上次访视恶化;仅3只眼符合失败或无效标准。
关键数值与推荐
- 雷珠单抗组前6个月每月注射,除非注射4次后达到消退。
- 6个月后若新生血管连续3次访视稳定(持续稳定)可暂缓注射;若新生血管恶化则恢复每月治疗。
- 符合失败或无效标准时可启动全视网膜光凝。
临床怎么用
- 对起始抗VEGF治疗的PDR患者,可按Protocol S算法进行每月注射及基于新生血管稳定性的暂缓/恢复调整。
- 新生血管消退者后续注射负担可能较低,但仍需密切随访,因暂缓注射后多数在16周内恢复治疗。
- 选择抗VEGF或全视网膜光凝作为一线治疗时,需结合两种疗法优势及患者随访依从性个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To present the rationale, guidelines, and results of ranibizumab treatment for proliferative diabetic retinopathy (PDR) in Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol S. DESIGN: Post hoc analyses from a randomized clinical trial. PARTICIPANTS: Three hundred five participants (394 study eyes) having PDR without prior panretinal photocoagulation (PRP). METHODS: Intravitreous ranibizumab (0.5 mg) versus PRP for PDR. Ranbizumab-assigned eyes (n = 191) received monthly injections for 6 months unless resolution was achieved after 4 injections. After 6 months, injections could be deferred if neovascularization was stable over 3 consecutive visits (sustained stability). If neovascularization worsened, monthly treatment resumed. Panretinal photocoagulation could be initiated for failure or futility criteria. MAIN OUTCOME MEASURES: Neovascularization status through 2 years. RESULTS: At 1 month, 19% (35 of 188) of ranibizumab-assigned eyes showed complete neovascularization resolution and an additional 60% (113) showed improvement. At 6 months, 52% (80 of 153) showed neovascularization resolution, 3% (4) were improved, 37% (56) were stable, and 8% (13) had worsened since the last visit. Among eyes with versus without resolved neovascularization at 6 months, the median (interquartile range) number of injections between 6 months and 2 years was 4 (1-7; n = 73) versus 7 (4-11; n = 67; P < 0.001). Injections were deferred in 68 of 73 eyes (93%) meeting sustained stability at least once during the study; 62% (42 of 68) resumed injections within 16 weeks after deferral. At 2 years, 43% (66 of 154) showed neovascularization resolution, 5% (7) showed improvement, 23% (36) were stable, and 27% (42) had worsened since the last visit. Only 3 eyes met criteria for failure or futility through 2 years. CONCLUSIONS: The DRCR.net treatment algorithm for PDR can provide excellent clinical outcomes through 2 years for patients initiating anti-vascular endothelial growth factor (VEGF) therapy for PDR. When choosing between anti-VEGF and PRP as first-line therapy for PDR, treatment decisions should be guided by consideration of the relative advantages of each therapeutic method and anticipated patient compliance with follow-up and treatment recommendations.
引用
- Sun JK, Glassman AR, Beaulieu WT, et al. Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy. Ophthalmology. 2018. PMID: 30096354. doi:10.1016/j.ophtha.2018.08.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。